RLAY
Relay Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$18.91
−0.54%Margins
Gross margin
-566.6%
EBITDA margin
-2771.8%
EBIT margin
-2999.4%
Net margin
-2763.6%
FCF margin
-2050.3%
-32.1%
Return on equity
-29.6%
Return on assets
-33.7%
Return on invested capital
0.01x
Asset turnover
-$212.2M
Cash from operations
$4.16
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026